Appendices

Appendix 1: December estimate of Australian population, 2012, by state or territory

	ACT	NSW	NT	Qld	SA	Tas.	Vic.	WA	Aus.
Source: ABS 3101.0 Table 4, Estimated Resident Population, State and Territories. Australian.
Males	186,598	3,624,791	123,542	2,278,280	820,358	255,419	2,785,448	1,227,524	11,304,018
Females	188,314	3,676,343	111,640	2,287,249	835,941	256,914	2,843,674	1,205,182	11,406,334
Total	374,912	7,301,134	235,182	4,565,529	1,656,299	512,333	5,629,122	2,432,706	22,710,352

Top of page

Appendix 2: December estimate of Australian population, 2012, by state or territory and age

Age group	State or territory								Aus.
	ACT	NSW	NT	Qld	SA	Tas.	Vic.	WA
Source : ABS 3101.0 Australian Demographic Statistics Tables, Dec 2012
0–4	25,195	480,038	18,781	311,523	99,079	31,700	360,280	162,596	1,489,345
5–9	22,507	455,948	17,670	301,108	96,396	31,081	340,546	154,160	1,419,580
10–14	21,139	445,081	16,778	296,587	97,808	32,522	330,483	151,020	1,391,602
15–19	23,923	462,924	16,183	304,996	105,080	33,905	355,158	157,336	1,459,675
20–24	33,667	501,133	19,310	327,882	115,164	31,779	412,430	182,303	1,623,931
25–29	33,720	527,163	22,688	334,501	114,359	30,153	434,210	199,306	1,696,561
30–34	30,258	510,800	20,077	310,952	104,359	28,895	406,697	178,784	1,591,154
35–39	27,700	499,769	18,188	313,767	104,210	30,313	391,802	170,380	1,556,350
40–44	27,400	513,719	18,096	331,264	116,468	35,224	411,666	181,443	1,635,528
45–49	24,654	488,206	15,975	308,608	113,425	34,719	378,544	168,351	1,532,695
50–54	24,334	493,244	15,300	304,242	115,408	37,857	371,151	161,965	1,523,710
55–59	20,982	443,610	12,994	269,621	105,640	35,320	333,395	144,353	1,366,102
60–64	18,487	397,667	9,899	245,049	97,240	32,973	297,065	125,461	1,224,010
65–69	14,272	338,845	6,327	205,263	82,689	27,937	249,660	98,553	1,023,622
70–74	9,712	252,602	3,775	146,489	61,301	20,615	188,476	72,402	755,425
75–79	6,997	195,763	1,943	104,763	48,369	15,171	146,607	53,271	572,906
80–84	5,225	154,209	1,190	78,889	39,517	11,431	115,351	39,964	445,791
85+	5,011	146,462	707	72,701	39,523	10,511	109,000	36,346	420,267
Total	375,183	7,307,183	235,881	4,568,205	1,656,035	512,106	5,632,521	2,437,994	22,728,254

Top of page

Appendix 3: Indigenous status, National Notifiable Diseases Surveillance System, Australia, 2012, by notifiable disease*

Disease name	Aboriginal but not TSI origin	TSI but not Aboriginal origin	Aboriginal and TSI origin	Not Indigenous	Not stated	Blank/ missing	Total	% complete	Number complete	Number incomplete
* Infection with Shiga toxin/verotoxin producing Escherichia coli. Indigenous status is usually obtained from medical notification and completeness varies by disease and by state and territory. TSI Torres Strait Islander
Arbovirus infection (NEC)	0	0	0	4	5	0	9	44	4	5
Barmah Forest virus infection	27	3	3	579	811	299	1,722	36	612	1,110
Brucellosis	1	0	0	19	9	0	29	69	20	9
Campylobacteriosis	143	9	11	8,085	7,405	0	15,653	53	8,248	7,405
Chlamydial infection	5,760	685	347	34,762	22,673	18,480	82,707	50	41,554	41,153
Cholera	0	0	0	5	0	0	5	100	5	0
Cryptosporidiosis	171	10	8	1,487	1,242	225	3,143	53	1,676	1,467
Dengue virus infection	10	0	2	1,215	276	38	1,541	80	1,227	314
Donovanosis	0	0	0	1	0	0	1	100	1	0
Gonococcal infection	3,529	233	142	4,930	2,533	2,282	13,649	65	8,834	4,815
Haemolytic uraemic syndrome	0	0	0	19	0	1	20	95	19	1
Haemophilus influenzae type b	2	0	0	13	0	0	15	100	15	0
Hepatitis A	0	0	0	148	16	1	165	90	148	17
Hepatitis B (newly acquired)	17	0	2	146	25	3	193	85	165	28
Hepatitis B (unspecified)	154	20	7	2,342	1,902	2,084	6,509	39	2,523	3,986
Hepatitis C (newly acquired)	83	0	1	321	50	11	466	87	405	61
Hepatitis C (unspecified)	620	10	17	3,123	3,474	2,404	9,648	39	3,770	5,878
Hepatitis D	2	0	0	24	4	0	30	87	26	4
Hepatitis E	0	0	0	31	4	0	35	89	31	4
Influenza (laboratory confirmed)	1,258	38	50	19,060	17,221	6,936	44,563	46	20,406	24,157
Japanese encephalitis virus infection	0	0	0	1	0	0	1	100	1	0
Legionellosis	6	0	2	327	42	5	382	88	335	47
Leprosy	0	0	0	4	0	0	4	100	4	0
Leptospirosis	2	0	0	98	14	2	116	86	100	16
Listeriosis	1	1	0	87	3	1	93	96	89	4
Malaria	0	2	0	280	62	4	348	81	282	66
Measles	12	0	0	182	5	0	199	97	194	5
Meningococcal disease (invasive)	22	3	0	187	11	0	223	95	212	11
Mumps	1	0	0	119	49	31	200	60	120	80
Murray Valley encephalitis virus infection	0	0	0	1	0	0	1	100	1	0
Ornithosis	1	0	0	39	34	1	75	53	40	35
Pertussis	512	20	17	11,086	9,674	2,760	24,069	48	11,635	12,434
Pneumococcal disease (invasive)	230	5	9	1,320	143	115	1,822	86	1,564	258
Q fever	12	1	0	263	74	8	358	77	276	82
Ross River virus infection	78	5	1	2,230	1,965	404	4,683	49	2,314	2,369
Rubella	1	0	0	25	10	0	36	72	26	10
Rubella - congenital	0	0	0	1	0	0	1	100	1	0
Salmonellosis	350	12	9	5,849	2,824	2,221	11,265	55	6,220	5,045
Shigellosis	147	0	0	332	40	28	547	88	479	68
STEC, VTEC*	3	0	0	91	16	1	111	85	94	17
Syphilis < 2 years	153	1	4	1,226	146	9	1,539	90	1,384	155
Syphilis > 2 years or unspecified duration	162	16	6	842	322	6	1,354	76	1,026	328
Tetanus	0	0	0	6	1	0	7	86	6	1
Tuberculosis	28	3	0	1,276	6	2	1,315	99	1,307	8
Typhoid fever	0	0	0	113	6	4	123	92	113	10
Varicella zoster (chickenpox)	121	3	5	1,654	181	0	1,964	91	1,783	181
Varicella zoster (shingles)	115	3	6	3,823	534	0	4,481	88	3,947	534
Varicella zoster (unspecified)	121	18	13	2,142	6,159	0	8,453	27	2,294	6,159
Total	13,855	1,101	662	109,918	79,971	38,366	243,872	51	125,536	118,337

Top of page

Acknowledgements

The authors wish to thank the following people for their contribution to this report.

Members of the National Surveillance Committee

The National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases

Top of page

Author details

Coordinating author: Rachael Corvisy

Data management: Mark Trungove

Bloodborne diseases: Amy Bright, Natasha Wood

Gastrointestinal diseases: Debra Gradie, Ben Polkinghorne

Quarantinable diseases: Katrina Knope

Sexually transmissible infections: Amy Bright, Natasha Wood

Vaccine preventable diseases: Kate Pennington, Bethany Morton, Rachel de Kluyver, Nicolee Martin

Vectorborne diseases: Katrina Knope

Zoonoses: Timothy Sloan-Gardner, Katrina Knope

Other bacterial infections: Cindy Toms, Kara Lengyel, Anna Glynn-Robinson

With contributions from:

Top of page

National organisations

Communicable Diseases Network Australia and subcommittees

Australian Childhood Immunisation Register

Australian Gonococcal Surveillance Programme

Australian Meningococcal Surveillance Programme

Australian Sentinel Practice Research Network

Australian Quarantine Inspection Service

The Kirby Institute for Infection and Immunity in Society

National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases

National Enteric Pathogens Surveillance Scheme

OzFoodNet Working Group

World Health Organization Collaborating Centre for Reference and Research on Influenza

State and territory health departments

Communicable Diseases Control, ACT Health, Australian Capital Territory

Communicable Diseases Surveillance and Control Unit, NSW Ministry of Health, New South Wales

Centre for Disease Control, Northern Territory Department of Health and Community Services, Northern Territory

Communicable Diseases Branch, Queensland Health, Queensland

Communicable Disease Control, South Australian Department of Health, South Australia

Communicable Diseases Prevention Unit, Department of Health and Human Services, Tasmania

Health Protection Branch, Department of Health and Human Services, Victoria

Communicable Diseases Control Directorate, Department of Health, Western Australia

Top of page

Abbreviations

7vPCV 7 valent pneumococcal conjugate vaccine

13vPCV 13 valent pneumococcal conjugate vaccine

23vPPV 23 valent pneumococcal polysaccharide vaccine

ABLV Australian bat lyssavirus

AFP acute flaccid paralysis

AGSP Australian Gonococcal Surveillance Programme

AIDS acquired immunodeficiency syndrome

AMSP Australian Meningococcal Surveillance Programme

ANCJDR Australian National Creutzfeldt-Jakob Disease Registry

BFV Barmah Forest virus

CDI Communicable Diseases Intelligence

CDNA Communicable Diseases Network Australia

CJD Creutzfeldt-Jakob disease

CRS congenital rubella syndrome

DENV dengue virus

HA haemagglutinin

HI haemagglutination inhibition

Hib Haemophilus influenzae type b

HIV human immunodeficiency virus

HPAIH highly pathogenic avian influenza in humans

HUS haemolytic uraemic syndrome

ILI influenza-like illness

IMD invasive meningococcal disease

IPD invasive pneumococcal disease

JEV Japanese encephalitis virus

KUNV Kunjin virus

MMR measles-mumps-rubella

MVEV Murray Valley encephalitis virus

NAMAC National Arbovirus and Malaria Advisory Committee

NDP no data provided

NEC not elsewhere classified

NIP National Immunisation Program

NN not notifiable

NNDSS National Notifiable Diseases Surveillance System

NQFMP National Q Fever Management Program

NSC National Surveillance Committee

NS1 non-structural protein 1

RNA ribonucleic acid

RRV Ross River virus

SARS severe acute respiratory syndrome

STEC Shiga toxin-producing Escherichia coli

STI(s) sexually transmissible infections(s)

TB tuberculosis

TSI Torres Strait Islander

VPD(s) vaccine preventable disease(s)

VTEC verotoxigenic Escherichia coli

VZV varicella zoster virus

WHO World Health Organization

WHOCC World Health Organization Collaborating Center

Top of page

References

1. National Health Security Act, 2007. Accessed on November 2009. Available from: http://www.legislation.gov.au/Details/C2007A00174
2. National Health Security (National Notifiable Disease List) Instrument 2008. Available from: http://www.legislation.gov.au/ComLaw/legislation/LegislativeInstrument1.nsf/0/7162D634C6DD1BAACA25740B0079D6B8?OpenDocument
3. National Health Security Agreement 2008. Accessed on November 2009. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-nhs-agreement.htm
4. The Kirby Institute. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report, 2012: The Kirby Institute, the University of New South Wales, Sydney; 2012.
5. Klug GM, Boyd A, McGlade A, Stehmann C, Simpson M, Masters CL, et al. Surveillance of Creutzfeldt-Jakob disease in Australia: update to December 2011. Commun Dis Intell 2012;36(2):E174–E179.
6. Australian Bureau of Statistics. Australian Demographic Statistics. Canberra: Australian Bureau of Statistics; 2011. Report No.: 3101.0.
7. Australian Institute of Health and Welfare. Age-standardised rate—Identifying and definitional attributes, 2005. Accessed on 17 March 2010. Available from: http://meteor.aihw.gov.au/content/index.phtml/itemId/327276
8. Graham S, Guy RJ, Donovan B, McManus H, El-Hayek C, Kwan K, et al. Epidemiology of chlamydia and gonorrhea among Indigenous and non-Indigenous Australians, 2000–2009. Med J Aust 2012;197(11):642–646.
9. Hammerschlag M. Sexually transmitted diseases in sexually abused children: medical and legal implications. Sex Transm Infect 1998;74(3):167–174.
10. Australian Institute of Health and Welfare. National Health Data Dictionary 13.3; 2008.
11. Chen MY, Fairley CK, Donovan B. Nowhere near the point of diminishing returns: correlations between chlamydia testing and notification rates in New South Wales. Aust N Z J Public Health 2005;29(3):249–253.
12. Hocking J, Fairley C, Counahan M, Crofts N. The pattern of notification and testing for genital Chlamydia trachomatis infection in Victoria, 1998–2000: an ecological analysis. Aust N Z J Public Health 2003;27(4):405–408.
13. Burckhardt F, Warner P, Young H. What is the impact of change in diagnostic test method on surveillance data trends in Chlamydia trachomatis infection? Sex Transm Infect 2006;82(1):24–30.
14. Chen MY, Karvelas M, Sundararajan V, Hocking JS, Fairley CK. Evidence for the effectiveness of a chlamydia awareness campaign: increased population rates of chlamydia testing and detection. Int J STD AIDS 2007;18(4):239–243.
15. Hammad A, Guy RJ, Fairley C, Wand H, Chen MY, Dickson B, et al. Understanding trends in genital Chlamydia trachomatis can benefit from enhanced surveillance: findings from Australia. Sex Transm Infect 2012;88(7):552–557.
16. Stephens N, O’Sullivan M, Coleman D, Shaw K. Chlamydia trachomatis in Tasmania 2001–2007: rising notification trends. Aust N Z J Public Health 2010;34(2):120–125.
17. National HBV Testing Policy Expert Reference Committee. National hepatitis B testing policy 2012 v1.1. ASHM, Darlinghurst, NSW: Commonwealth of Australia; 2012.
18. National HCV Testing Policy Expert Reference Committee. National hepatitis C testing policy 2012 v1.1. ASHM, Darlinghurst, NSW: Commonwealth of Australia; 2012.
19. Heymann DL. Control of Communicable Diseases Manual. 19th edn. Washington: American Public Health Association, USA; 2008.
20. Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th edn. Canberra, Australia: National Health and Medical Research Council and the Department of Health and Ageing; 2013.

Top of page

21. Hull BP, Dey A, Menzies RI, Brotherton JM, McIntyre PB. Immunisation coverage, 2012. Commun Dis Intell 2014;38(3):E208–231.
22. The Kirby Institute. National Blood-borne Virus and Sexually Transmissible Infections Surveillance and Monitoring Report 2013. Sydney, NSW: The Kirby Institute, the University of New South Wales; 2013.
23. Butler T, Lim D, Callander D. National Prison Entrants’ Bloodborne Virus and Risk Behaviour Survey Report 2004, 2007 and 2010. Prevalence of HIV, hepatitis C, hepatitis B, sexually transmissible infections, and risk behaviours among Australian prison entrants; 2011.
24. Gidding HF, Warlow M, MacIntyre CR, Backhouse J, Gilbert GL, Quinn HE, et al. The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine 2007;25(51):8637–8641.
25. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007;91(2–3):228–235.
26. The Kirby Institute. National Blood-borne Virus and Sexually Transmissible Infections Surveillance and Monitoring Report 2011. Sydney, NSW: The Kirby Institute, the University of New South Wales; 2012.
27. OzFoodNet Working Group. Monitoring the incidence and causes of diseases potentially transmitted by food in Australia: Annual report of the OzFoodNet Network, 2010. Commun Dis Intell 2012;36(3):E213–E241.
28. Donnan EJ, Fielding JE, Gregory JE, Lalor K, Rowe S, Goldsmith P, et al. A multistate outbreak of hepatitis A associated with semidried tomatoes in Australia, 2009. Clin Infect Dis 2012;54(6):775–781.
29. Cumpston JHL. Health and disease in Australia. Canberra: Australian Government Publishing Service; 1989.
30. Grattan-Smith PJ, O’Regan WJ, Ellis PS, O’Flaherty SJ, McIntyre PB, Barnes CJ. Rabies. A second Australian case with a long incubation period. Med J Aust 1992;156(9):651–654.
31. Fenner F, Henderson D, Arita I, Jezek Z, Ladnyi I. Smallpox and its eradication. Geneva, Switzerland; 1988.
32. Australian Government Department of Health and Ageing. Guidelines for smallpox outbreak, preparedness, response and management. 2004. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/health-pubhlth-publicat-document-metadata-smallpox.htm
33. NNDSS Annual Report Writing Group. Australia’s notifiable disease status, 2011: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2013;37(4):E313–393.
34. Miller M, Roche P, Yohannes K, Spencer J, Bartlett M, Brotherton J, et al. Australia’s notifiable diseases status, 2003: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2005;29(1):1–61.
35. World Health Organization. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. 2013. Available from: http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html
36. Curran M, Harvey B, Crerar S. Annual report of the National Notifiable Diseases Surveillance System, 1996. Commun Dis Intell 1997;21(20):281–307.
37. Forssman B, Mannes T, Musto J, Gottlieb T, Robertson G, Natoli JD, et al. Vibrio cholerae O1 El Tor cluster in Sydney linked to imported whitebait. Med J Aust 2007;187(6):345–347.
38. Regan DG, Wilson DP, Hocking JS. Coverage is the key for effective screening of Chlamydia trachomatis in Australia J Infect Dis 2008;198(3):349–358.
39. Victoria Department of Health. Blue book: Guidelines for the control of infectious diseases. 2009. Accessed on 3 April 2014. Available from: http://ideas.health.vic.gov.au/bluebook/
40. Bowden FJ, on behalf of the National Donovanosis Eradication Advisory Committee. Donovanosis in Australia: going, going... Sex Transm Infect 2005;81(5):365–366.

Top of page

41. Lahra MM, Enriquez RP. Australian Meningococcal Surveillance Programme annual report, 2012. Commun Dis Intell 2013;37(3):E224–E232.
42. The Kirby Institute. HIV, viral hepatitis and sexually transmissable infections in Australia Annual Surveillance Report 2013. Sydney: The Kirby Institute, The University of New South Wales; 2013.
43. Government of Western Australia. Department of Health. The Epidemiology of Notifiable Sexually Transmitted Infections and Blood-Borne Viruses in Western Australia 2009. Perth: Department of Health, Western Australia; 2010.
44. Ward J, Guy RJ, Akre S, Middleton M, Giele C, Su J, et al. Epidemiology of syphilis in Australia: moving toward elimination of infectious syphilis from Aboriginal and Torres Strait Islander communities? Med J Aust 2011;194(10):525–529.
45. Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Vaccine Preventable Diseases in Australia, 2005 to 2007. Commun Dis Intell 2010;34(Suppl):S1–S172.
46. Pillsbury A, Quinn HE, McIntyre PB. Australian vaccine preventable disease epidemiological review series: pertussis, 2006–2012. Commun Dis Intell 2014;38(3):E179–194.
47. Chiew M, Dey A, Martin N, Wang H, Davis S, McIntyre PB. Australian vaccine preventable disease epidemiological review series: measles 2000–2011. Commun Dis Intell 2015;39(1):E1–E9.
48. Bag SK, Dey A, Wang H, Beard F. Australian vaccine preventable disease epidemiological review series: mumps 2008–2012. Commun Dis Intell 2015;39(1):E10–E18.
49. Chan J, Dey A, Wang H, Martin N, Beard F. Australian vaccine preventable disease epidemiological review series: rubella 2008–2012. Commun Dis Intell 2015;39(1):E19–E26.
50. Punpanich W, Chotpitayasunondh T. A review on the clinical spectrum and natural history of human influenza. Int J Infect Dis 2012;16(10):e714–e723.
51. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008;167(7):775–785.
52. Mauskopf J, Klesse M, Lee S, Herrera-Taracena G. The burden of influenza complications in different high-risk groups: a targeted literature review. J Med Economics 2013;16(2):264–277.
53. Sosin DM. Draft framework for evaluating syndromic surveillance systems. J Urban Health 2003;80(Suppl 1):8–13.
54. Turbelin C, Souty C, Pelat C, Hanslik T, Sarazin M, Blanchon T, et al. Age distribution of influenza like illness cases during post-pandemic A(H3N2): comparison with the twelve previous seasons, in France. PLoS One 2013;8(6):e65919.
55. Schepetiuk SK, T. K. The use of MDCK, MEK and LLC-MK2 cell lines with enzyme immunoassay for the isolation of influenza and parainfluenza viruses from clinical specimens. J Virol Methods 1993;42(2–3):241–250.
56. Review of the 2012 winter influenza season, southern hemisphere. Wkly Epidemiol Rec 2012;87(44):422–431.
57. Stocks N. Australian Sentinel Practice Research Network. In: Surveillance systems reported in Communicable Diseases Intelligence, 2013. Commun Dis Intell 2013;37(1):E62.
58. Carlson SJ, Dalton CB, Butler MT, Fejsa J, Elvidge E, Durrheim DN. Flutracking weekly online community survey of influenza-like illness annual report, 2011 and 2012. Commun Dis Intell 2013;37(4):E398–E406.
59. Health Protection NSW. Influenza epidemiology report: December 2012 and summary for 2012. In: Influenza Monthly Epidemiology Report, NSW. 2012 Influenza Reports: NSW Government; 2013.
60. Northern Territory Department of Health and Community Services. Comments on notifications. Northern Territory Disease Control Bulletin 2012;19(1):29.

Top of page

61. Hjuler T, Poulsen G, Wohlfahrt J, Kaltoft M, Biggar RJ, Melbye M. Genetic susceptibility to severe infection in families with invasive pneumococcal disease. Am J Epidemiol 2008;167(7):814–819.
62. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases.Significant events in pneumococcal vaccination practice in Australia. Accessed on 20 January 2014. This document was available from:http://www.ncirs.edu.au/immunisation/history/Pneumococcal-history-July-2014.pdf at the time of writing
63. Bareja C, Toms C, Lodo K, de Kluvyer R, Enhanced Invasive Pneumococcal Disease Surveillance Working Group. Invasive pneumococcal disease in Australia, 2009 and 2010. Commun Dis Intell 2015;39(2):In Press.
64. Centers for Disease Control and Prevention. Measles. In: Atkinson W, Wolfe C, Hamborsky J, eds. Epidemiology and prevention of vaccine preventable diseases. 12th edn. Washington, D.C.: Public Health Foundation; 2011.
65. World Health Organization. Measles. Geneva; 2014.
66. Strebel P, Papania M, Dayan G, Halsey N. Vaccines. Philadelphia: Saunders Elsevier; 2008.
67. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ 2010;340:10.1136/bmj.c1626.
68. Rosewell A, Reinten-Reynolds T, Spokes P. Measles in NSW, 2002–2011. N S W Public Health Bull 2012;23(9–10):201–207.
69. Gidding H, Wood J, MacIntyre CR, Kelly H, Lambert SB, Gilbert GL, et al. Sustained measles elimination in Australia and priorities for long-term maintenance. Vaccine 2007;25(18):3574–3580.
70. Gidding HF, Gilbert GL. Measles immunity in young Australian adults. Commun Dis Intell 2001;25(3):133–136.
71. Heywood AE, Gidding HF, Riddell MA, McIntyre PB, MacIntyre CR, Kelly HA. Elimination of endemic measles transmission in Australia. Bull World Health Organ 2009;87(1):64–71.
72. Gay NJ, De Serres G, Farington P, Redd SB, Papania MJ. Assessment of the status of measles elimination from reported outbreaks: United States, 1997–1999. J Infect Dis 2004;189(Suppl 1):S36–S42.
73. Plotkin SA. The history of rubella and rubella vaccination leading to elimination. Clin Infect Dis 2006;43(Suppl 3):S164–S168.
74. Aratchige PE, McIntyre PB, Quinn HE, Gilbert GL. Recent increases in mumps incidence in Australia: the “forgotten” age group in 1998 Australian Measles Control Campaign. Med J Aust 2008;189(8):4.
75. Gupta R, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ 2005;330:1132–1135.
76. Deeks S, Lim G, Simpson M, Gagné L, Kristjanson E, Fung C, et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. Can Med Assoc J 2011;183(9):1014–1020.
77. Demicheli V, Rivetti A, Debalini M, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Chochrane Database Sys Rev 2012;2:CD004407.
78. Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, et al. Recent resurgence of mumps in the United States. N Engl J Med 2008;358(15):1580–1589.
79. Whelan J, Van Binnendijk R, Greenland K, Fanoy E, Kharqi M, Yap K, et al. Ongoing mumps outbreak in a student population with high vaccination coverage, Netherlands. Euro Surveill 2010;15(17):pii:19554.
80. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, et al. Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. Emerg Infect Dis 2007;13(1):12–17.

Top of page

81. Pertussis. In: Atkinson W, Wolfe C, Hamborsky J, eds. Epidemiology and prevention of vaccine preventable diseases. 12th edn. Washington, DC: Public Health Foundation, Centers for Disease Control and Prevention; 2011.
82. Britt H, Miller GC, Charles J, Henderson J, Bayram C, Pan Y, et al. General practice activity in Australia 2009–10. Canberra: Australian Institute of Health and Welfare; 2010.
83. Communicable Diseases Network Australia. Series of National Guidelines: Pertussis. 2013. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-pertussis.htm
84. Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995–2005—trends by region and age group. Commun Dis Intell 2007;31(2):205–215.
85. Quinn HE, Mahajan D, Hueston L, Campbell P, Menzies RI, Gilbert GL, et al. The seroepidemiology of pertussis in NSW: fluctuating immunity profiles related to changes in vaccination schedules. N S W Public Health Bull 2011;22(11–12):224–229.
86. Kaczmarek M, Lambert S, Kelly H, Ware R, Valenti L, Britt H. Seven-fold rise in likelihood of pertussis-test requests during Australian GP encounters, 2000–2011. In: 13th National Immunisation Conference. Darwin Convention Centre, Darwin, NT: Public Health Association of Australia; 2012.
87. Sheridan S, Ware R, Grimwood K, Lambert S. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012;308(5):454–456.
88. Misegades L, Winter K, Harriman K, Talarico J, Messonnier NE, Clark T, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012;308(20):2126–2132.
89. Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013;131(4):e1047–e1052.
90. Quinn HE. Pertussis vaccine effectiveness in Australia [abstract]. In: National pertussis workshop: strategies to prevent severe pertussis in the next decade. Sydney Australia: National Centre for Immunisation and Research of Vaccine Preventable Diseases; 2011.
91. Australian Technical Advisory Group on Immunisation. Bulletin 44th meeting 24–25 February 2011.
92. Roberts J, Hobday L, Ibrahim A, Aitken T, Thorley B. Annual report of the Australian National Enterovirus Reference Laboratory 2012. Commun Dis Intell 2013;37(2):E97–E104.
93. Song N, Gao Z, Wood JG, Hueston L, Gilbert GL, MacIntyre CR, et al. Current epidemiology of rubella and congenital rubella syndrome in Australia: progress towards elimination. Vaccine 2012;30(27):4073–4078.
94. Nelson MR, Britt HC, Harrison CM. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med J Aust 2010;193(2):110–113.
95. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009;27(4):520–529.
96. Carville KS, Grant KA, Kelly HA. Herpes zoster in Australia. Epidemiol Infect 2012;140(04):599–601.
97. Knope K, Whelan P, Smith D, Johansen C, Moran R, Doggett S, et al. Arboviral diseases and malaria in Australia, 2010–11: annual report of the National Arbovirus and Malaria Advisory Committee. Commun Dis Intell 2013;37(1):E1–E20.
98. Mackenzie JS, Lindsay MD, Coelen RJ, Broom AK, Hall RA, Smith DW. Arboviruses causing human disease in the Australasian zoogeographic region. Arch Virol 1994;136(3–4):447–467.
99. Russell RC, Dwyer DE. Arboviruses associated with human disease in Australia. Microbes Infect 2000;2(14):1693–1704.
100. Viennet E, Knope K, Faddy H, Williams C, Harley D. Assessing the threat of chikungunya emergence in Australia. Commun Dis Intell 2013;37(2):E136–E143.

Top of page

101. Communicable Diseases Network Australia. Australian National Notifiable Diseases Case Definitions. 2013. Accessed on 5 September 2013. Available from: http://www.health.gov.au/casedefinitions
102. Therapeutic Goods Administration. Product recall, Panbio Barmah Forest Virus IgM ELISA. An in vitro diagnostic medical device (IVD). Recall no. RC-2013-RN-00967-1,13/09/2013. 2013. Accessed on 6 May 2014. Available from: http://www.tga.gov.au/SARA/arn-detail.aspx?k=RC-2013-RN-00967-1
103. Guzman MG, Kouri G, Martinez E, Bravo J, Riveron R, Soler M, et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ 1987;21(3):270–279.
104. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181(1):2–9.
105. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nature Medicine 2004;10(12 Suppl):S98–S109.
106. Hanna JN, Ritchie SA, Richards AR, Humphreys JL, Montgomery BL, Ehlers GJ, et al. Dengue in north Queensland, 2005–2008. Commun Dis Intell 2009;33(2):198–203.
107. Queensland Health. Queensland Dengue Management Plan 2010–2015, 2011. Queensland: Queensland Health.
108. Knope K, National Arbovirus and Malaria Advisory Committee, Giele C. Increasing notifications of dengue related to overseas travel, 1991 to 2012. Commun Dis Intell 2013;37(1):E55–E59.
109. Hanna JN, Ritchie SA, Phillips DA, Lee JM, Hills SL, van den Hurk AF, et al. Japanese encephalitis in north Queensland, Australia, 1998. Med J Aust 1999;170(11):533–536.
110. Roche S WR, Garner M, East I, Paskin R, Moloney B, Carr M, Kirkland P. Descriptive overview of the 2011 epidemic of arboviral disease in horses in Australia. Aust Vet J 2013;91(1–2):5–13.
111. Knox J, Cowan RU, Doyle JS, Ligtermoet MK, Archer JS, Burrow JN, et al. Murray Valley encephalitis: a review of clinical features, diagnosis and treatment. Med J Aust 2012;196(5):322–326.
112. Frost MJ, Zhang J, Edmonds JH, Prow NA, Gu X, Davis R, et al. Characterization of virulent West Nile virus Kunjin strain, Australia, 2011. Emerg Infect Dis 2012;18(5):792–800.
113. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008;46(2):165–171. doi: 110.1086/524888.
114. World Health Organization. Synopsis of the world malaria situation in 1981. Wkly Epidemiol Rec 1983;58(26):197–199.
115. Leder K, Torresi J, Brownstein JS, Wilson ME, Keystone JS, Barnett E, et al. Travel-associated illness trends and clusters, 2000–2010. Emerg Infect Dis 2013;19(7):1049–1073.
116. Gray TJ, Trauer JM, Fairley M, Krause VL, Markey PG. Imported malaria in the Northern Territory, Australia—428 consecutive cases. Commun Dis Intell 2012;36(1):107–113.
117. Preston-Thomas A, Gair RW, Hosking KA, Devine GJ, Donohue SD. An outbreak of Plasmodium falciparum malaria in the Torres Strait. Commun Dis Intell 2012;36(2):E180–E185.
118. Hanna JN, Ritchie SA, Eisen DP, Cooper RD, Brookes DL, Montgomery BL. An outbreak of Plasmodium vivax malaria in Far North Queensland, 2002. Med J Aust 2004;180(1):24–28.
119. World Health Organization. Zoonoses. Technical report series no. 169. Geneva, Switzerland: World Health Organization; 1959.
120. Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence. Philos Trans R Soc Lond B Biol Sci 2001;356(1411):983–989.

Top of page

121. Jones KE, Patel NG, Levy MA. Global trends in emerging infectious diseases. Nature 2008(451):990–994.
122. Woolhouse MEJ, Gowtage-Sequeria S. Host range and emerging and re-emerging pathogens. Emerg Infect Dis 2005;11(12):1842–1847.
123. World Health Organization. Report of the WHO/FAO/OIE joint consultation on emerging zoonotic diseases. Geneva, Switzerland: World Health Organization; 2004.
124. Animal Health Australia. Animal Health in Australia 2012. Canberra; 2013.
125. Kolbe A, Yuen M, Doyle B. A case of human cutaneous anthrax. Med J Aust 2006;185(5):281–282.
126. Fielding J. Zoonoses: Anthrax. Vic Infect Dis Bull 2007;10(2):47.
127. NSW Department of Health. Communicable Diseases Report, NSW, January and February 2010. N S W Public Health Bull 2010;21(3–4):103–107.
128. Calisher CH, Ellison JA. The other rabies viruses: The emergence and importance of lyssaviruses from bats and other vertebrates. Travel Med Infect Dis 2012;10(2):69–79.
129. Fraser GC, Hooper PT, Lunt RA, Gould AR, Gleeson LJ, Hyatt AD, et al. Encephalitis caused by a lyssavirus in fruit bats in Australia. Emerg Infect Dis 1996;2(4):327–331.
130. Hooper PT, Lunt RA, Gould AR, Samaratunga H, Hyatt AD, Gleeson LJ, et al. A new lyssavirus — the first endemic rabies-related virus recognized in Australia. Bulletin de l’Institut Pasteur 1997;95(4):209–218.
131. Communicable Diseases Network Australia. Series of National Guidelines: Rabies virus and other lyssavirus including Australian bat lyssavirus) exposures and infections. 2013. Accessed on 7 June 2013. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-abvl-rabies.htm
132. Allworth A, Murray K, Morgan J. A human case of encephalitis due to a lyssavirus recently identified in fruit bats. Commun Dis Intell 1996;20(24):504.
133. Hanna JN, Carney IK, Smith GA, Tannenberg AEG, Deverill JE, Botha JA, et al. Australian bat lyssavirus infection: a second human case, with long incubation period. Med J Aust 2000;172(12):597–599.
134. Francis JR, Nourse C, Vaska VL, Calvert S, Northill JA, McCall B, et al. Australian bat lyssavirus in a child: The first reported case. Pediatrics 2014;133(4):e1063–1067.
135. Queensland Department of Agriculture Fisheries and Forestry. Australian bat lyssavirus veterinarian communiqué, 21 May 2013. Accessed on 7 July 2013. Available from: http://www.vsbsa.org.au/images/File/ABLV%20vet%20communique%2021%20May%202013.pdf
136. Queensland Department of Agriculture Fisheries and Forestry. Australian bat lyssavirus update communiqué 7 June 2013. Accessed on 7 July 2013. Available from: http://www.ava.com.au/sites/default/files/Lyssavirus%20communique%20130607.pdf
137. Australian Bat Lyssavirus Focus Group. Australian Bat Lyssavirus report, December 2012: Australian Wildlife Health Network; 2012.
138. Eales KM, Norton RE, Ketheesan N. Brucellosis in northern Australia. Am J Trop Med Hyg 2010;83(4):876–878.
139. World Health Organization. Human leptospirosis : guidance for diagnosis, surveillance and control. Geneva, Switzerland: World Health Organization; 2003.
140. Levett PN. Leptospirosis. Clin Microbiol Rev 2001;14(2):296–326.

Top of page

141. O’Leary FM, Hunjan JS, Bradbury R, Thanakrishnan G. Fatal leptospirosis presenting as musculoskeletal chest pain. Med J Aust 2004;180(1):29–31.
142. Smith JK, Young MM, Wilson KL, Craig SB. Leptospirosis following a major flood in Central Queensland, Australia. Epidemiol Infect 2012;141(3):1–6.
143. Queensland Health. Statewide Weekly Communicable Diseases Surveillance Report, 4 April 2011: Epidemiology, Surveillance and Research Unit; 2011.
144. Beeckman DS, Vanrompay DC. Zoonotic Chlamydophila psittaci infections from a clinical perspective. Clin Microbiol Infect 2009;15(1):11–17.
145. Deschuyffeleer TP, Tyberghien LF, Dickx VL, Geens T, Saelen JM, Vanrompay DC, et al. Risk assessment and management of Chlamydia psittaci in poultry processing plants. Ann Occup Hyg 2012;56(3):340–349.
146. Department of Health Victoria. Communicable disease surveillance October–December 2011. Victorian Infectious Diseases Bulletin 2012;15(1):21–39.
147. Department of Health Victoria. Communicable disease surveillance October–December 2012. Victorian Infectious Diseases Bulletin 2013;16.
148. McCaul TF, Williams JC. Developmental cycle of Coxiella burnetii: structure and morphogenesis of vegetative and sporogenic differentiations. J Bacteriol 1981;147(3):1063–1076.
149. Lowbridge CP, Tobin S, Seale H, Ferson MJ. Notifications of Q fever in NSW, 2001–2010. N S W Public Health Bull 2012;23(1–2):31–35.
150. Bell M, Patel M, Sheridan J. Q fever vaccination in Queensland abattoirs. Commun Dis Intell 1997;21(3):29–31.
151. Lin M, Delpech V, McAnulty J, Campbell-Lloyd S. Notifications of Q fever in New South Wales, 1991–2000: EpiReview. N S W Public Health Bull 2001;12(6):172–175.
152. Gidding HF, Wallace C, Lawrence G, McIntyre PB. Australia’s National Q Fever Vaccination Program. Vaccine 2009;27(14):2037–2041.
153. Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev 2002;15(4):631–646.
154. Jackson J, McGregor A, Cooley L, Ng J, Brown M, Ong CW, et al. Francisella tularensis subspecies holarctica, Tasmania, Australia, 2011. Emerg Infect Dis 2012;18(9):1484–1486.
155. Veitch M. The public health response to tularaemia in Tasmania. Communicable Disease Control Conference 2013. Canberra, Australia; 2013.
156. Health Protection NSW. Year in review: Health Protection in NSW, 2012. NSW Public Health Bulletin 2013;24(3):107–118.
157. Victorian Department of Health. Communicable disease surveillance, Victoria, October–December 2012. Victorian Infectious Diseases Bulletin 2013;16(1):27–47.
158. Campese C, Bitar D, Jarraud S, Maine C, Forey F, Etienne J, et al. Progress in the surveillance and control of Legionella infection in France, 1998–2008. Int J Infect Dis 2011;15(1):e30–37.
159. Hartemann P, Hautemaniere A. Legionellosis prevention in France. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2011;54(6):724–727.
160. Legionellosis. In: Heymmann D, ed. Control of Communicable Diseases Manual. 19th edn. Washington: American Public Health Association; 2008. p. 337–340.
161. Communicable Diseases Network Australia. Guidelines for the early clinical and public health management of meningococcal disease in Australia. Revised edition 2007. Accessed on 6 November 2013. Available from: http://webarchive.nla.gov.au/gov/20140801082945/http://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-other-mening-2007.htm
162. Communicable Diseases Network Australia. Surveillance Case Definitions for the Australian National Notifiable Diseases Surveillance System. 2004. Accessed on 25 June 2012. Available from: http://www.health.gov.au/casedefinitions
163. Hull B, Dey A, Menzies R, McIntyre P. Annual immunisation coverage report, 2010. Commun Dis Intell 2013;37(1):E21–E39.
164. World Health Organization. Tuberculosis. Fact Sheet number 104. 2014. Accessed on 13 October 2014. Available from: http://www.who.int/mediacentre/factsheets/fs104/en/
165. Toms C, Stapledon R, Waring J, Douglas P, National Tuberculosis Advisory Committee for the Communicable Diseases Network Australia. Tuberculosis notifications in Australia, 2012 and 2013. Commun Dis Intell 2015;39(2):In Press.

Top of page